SCHEMBL6563313

SCHEMBL6563313

CCOC(=O)CSc1nc(Cl)cc(Nc2cccc(C(F)(F)F)c2)n1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 2/20 0.64
PPARA Q07869 7/20 0.58
PPARG P37231 6/20 0.58
RXRA P19793 4/20 0.58
RXRG P48443 4/20 0.58
PPARD Q03181 3/20 0.58
F2 P00734 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
RXRB P28702 3/20 0.48
ALDH1A1 P00352 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
MAPK1 P28482 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
KDM4E B2RXH2 1/20 0.48
MEN1 O00255 1/20 0.48
ABCC4 O15439 1/20 0.48
ABCB11 O95342 1/20 0.48
CYP3A4 P08684 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6565628 0.86 PPARA (0.72) ALOX5PPARAPPARGRXRARXRG
SCHEMBL6563923 0.82 ALOX5 (0.68) ALOX5PPARAPPARGRXRARXRG
SCHEMBL6561975 0.81 ALOX5 (0.70) ALOX5PPARAPPARGRXRARXRG
SCHEMBL6565546 0.80 ALOX5 (0.68) ALOX5PPARAPPARGRXRARXRG
SCHEMBL6565607 0.79 ALOX5 (0.67) ALOX5PPARAPPARGRXRARXRG
SCHEMBL6565495 0.78 PPARA (0.77) ALOX5PPARAPPARGRXRARXRG
SCHEMBL11840409 0.76 ALOX5 (0.59) ALOX5PPARAPPARGRXRARXRG
SCHEMBL6563326 0.75 ALOX5 (0.61) ALOX5PPARAPPARGRXRARXRG
SCHEMBL6827151 0.75 KDM4E (0.58) ALOX5ALDH1A1MAPK1L3MBTL1KDM4E
SCHEMBL6464917 0.72 KDM4E (0.60) F2CYP1A2CYP2C9CYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1399426-A2 COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING BETA-AMYLOID PRODUCTION Active Pass Pharmaceuticals, Inc. (CA) 2004-03-24 EP disclosed
US-20030191144-A1 Compounds, compositions and methods for modulating beta-amyloid production ACTIVE PASS PHARMACEUTICALS, INC. (CA) 2003-10-09 US disclosed
US-20030125338-A1 Compounds, compositions and methods for modulating beta-amyloid production ACTIVE PASS PHARMACEUTICALS, INC. (CA) 2003-07-03 US disclosed
WO-2002100836-A2 COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING BETA-AMYLOID PRODUCTION ACTIVE PASS PHARMACEUTICALS, INC. (CA) 2002-12-19 WO disclosed
US-3940394-A ANTILIPEMIC SANTILLI ARTHUR A 1976-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030125338-A1 Compounds, compositions and methods for modulating beta-amyloid production APP, PPARA, PPARG ALOX5 197/4885PPARA 2/4885PPARG 3/4885
US-20030191144-A1 Compounds, compositions and methods for modulating beta-amyloid production APP, PPARA, PPARG ALOX5 197/4885PPARA 2/4885PPARG 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.